Corcept Therapeutics CORT Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 98.3%-0.1pp | 98.4%-0.3pp | 98.7%0.0pp | 98.7%+0.1pp | |
| Operating margin | 5.9%-14.4pp | 20.3%-2.0pp | 22.2%-5.8pp | 28%-6.0pp | |
| Net margin | 13.1%-7.8pp | 20.9%-1.1pp | 22%-3.2pp | 25.2%-5.5pp | |
| Returns | |||||
| Return on equity | 15%-8.8pp | 23.8%+2.8pp | 21%-2.1pp | 23.1%-1.9pp | |
| Return on invested capital | 8.2%-17.6pp | 25.8%+3.1pp | 22.6%-4.1pp | 26.7%-3.2pp | |
| Efficiency | |||||
| Asset turnover | 0.9×0.0× | 0.9×+0.1× | 0.8×0.0× | 0.8×+0.1× | |
| Liquidity | |||||
| Current ratio | 2.9×-0.4× | 3.4×-1.0× | 4.4×-2.5× | 6.9×+1.3× | |
| Leverage | |||||
| Debt-to-equity | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Net debt / EBITDA | -2.5×-1.6× | -0.9×+0.4× | -1.3×-0.7× | -0.6×0.0× | |
| Per Share | |||||
| Book value per share | $5.40-9.8% | $5.99+32.1% | $4.53+4.8% | $4.33+45.0% | |
| Valuation | |||||
| Market capitalization | $3.66B-30.7% | $5.28B+57.7% | $3.35B+53.1% | $2.19B-4.4% | |
| Price / earnings | 36.7×-0.7× | 37.4×+5.8× | 31.5×+10.0× | 21.6×+1.2× | |
| Price / sales | 4.8×-3.0× | 7.8×+0.9× | 6.9×+1.5× | 5.4×-0.8× | |
| Price / book | 5.7×-2.1× | 7.8×+1.2× | 6.6×+2.3× | 4.4×-1.7× | |
| EV / EBITDA | 77.2×+39.7× | 37.4×+7.8× | 29.7×+11.0× | 18.6×+1.3× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Corcept Therapeutics's profit margins?
- Corcept Therapeutics (CORT) runs a 98.3% gross margin and a -1.1% operating margin, with a 6.2% net margin.
- Where do Corcept Therapeutics's ratios come from?
- Every ratio is computed from Corcept Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
